Disparities and trends in biomarker testing in metastatic colorectal cancer.
HR Robinson, J Hu, NB Balmaceda, RW Lentz… - 2024 - ascopubs.org
29 Background: Several therapies with biomarker-based indications have received
approvals for use in metastatic colorectal cancer (mCRC) in the past decade. Consequently …
approvals for use in metastatic colorectal cancer (mCRC) in the past decade. Consequently …
Understanding the efficacy of frontline therapies for hepatocellular carcinoma through etiologic stratification.
M Goryachok, J Hu, RW Lentz, WA Messersmith… - 2024 - ascopubs.org
491 Background: Despite significant advancements in recent years, hepatocellular
carcinoma (HCC) treatment options remain limited for patients who progress on locoregional …
carcinoma (HCC) treatment options remain limited for patients who progress on locoregional …
43 Implementation, practise and experiences of an international online multidisciplinary tumour board (IMDTB) with a cancer centre in northwest region of cameroon
S Hentsch, KF Tchintseme, A Ivo, B Rebecca, H Larissa… - 2020 - ijgc.bmj.com
Introduction/Background Multidisciplinary tumour boards (MDTBs) are universally
recommended. Nevertheless access to MDTBs, especially in low-income countries and rural …
recommended. Nevertheless access to MDTBs, especially in low-income countries and rural …